Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVenture Life Regulatory News (VLG)

Share Price Information for Venture Life (VLG)

Share Price is delayed by 15 minutes
Get Live Data
65.50    -0.50 (-0.76%)
Bid:
65.00
Ask:
66.00
Spread: 1.00 (1.538%)
Market Cap: £79.80m
VLG Live PriceLast checked at - London Stock Exchange

Intraday Venture Life Share Chart

Director/PDMR Shareholding

4 Jun 2026 07:00

RNS Number : 9188G
Venture Life Group PLC
04 June 2026
Ā 

4 June 2026

VENTURE LIFE GROUP PLC

("Venture Life", "VLG" or the "Company")

Director/PDMR Shareholding

Venture LifeĀ (AIM: VLG), a recognised leader in proactive longevity, health innovation and global commercialisation within the global consumer healthcare sector, announces that Paul McGreevy, Non-Executive Chairman, purchased 88,273 ordinary shares of 0.3 pence each in the capital of the Company ("Ordinary Shares") on 3 June 2026 at a volume-weighted average price of 62.3 pence per Ordinary Share.

Following the purchase, Mr McGreevy beneficially holds 1,052,098 Ordinary Shares representing approximately 0.82 per cent. of the Company's issued share capital.

Ā 

For further information, please contact:

Ā 

Venture Life Group PLC

+44 (0) 1344 578004

Jerry Randall, Chief Executive Officer

Daniel Wells, Chief Financial Officer

Ā 

Cavendish Capital Markets Limited (Nomad and Broker)

Ā 

+44 (0) 20 7720 0500

Stephen Keys / George Lawson / Joe SmithĀ (Corporate Finance)

Michael Johnson (Sales)

Ā 

Ā 

AboutĀ Venture LifeĀ (www.venture-life.com)

Venture LifeĀ is an international consumer self-care company focused on commercialising products for the global self-care market. Headquartered in theĀ UK, the Group's product portfolio includes Balance Activ in the area of women's intimate healthcare, EarolĀ® supporting ENT care, Lift and Glucogel product ranges for energy and glucose management and hypoglycaemia, plus the Health & Her product range supporting the hormonal lifecycle.

The products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through health & beauty stores, pharmacies, grocery multiples and e-commerce channels and are sold globally. In theĀ UK, IrelandĀ and the USA these are supplied direct by the company to retailers, elsewhere they are supplied by the Group's international distribution partners.Ā 

Ā 

The Company makes the following disclosure in accordance with article 19(3) of the Market Abuse Regulation:

1

Ā 

Details of the person discharging managerial responsibilities / person closely associated

Ā 

a)

Ā 

Name

Ā 

Paul McGreevy

2

Ā 

Reason for the notification

Ā 

a)

Ā 

Position/status

Ā 

Non-Executive Chairman

b)

Ā 

Initial notification /Amendment

Ā 

Initial notification

3

Ā 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

Ā 

a)

Ā 

Name

Ā 

Venture Life Group plc

b)

Ā 

LEI

Ā 

213800S8CZUPLAB2KC70

4

Ā 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

Ā 

a)

Ā 

Description of the financial instrument, type of instrument

Ā 

Ā 

Identification code

Ā 

Ordinary Shares of 0.3p each in Venture Life Group plc

Ā 

Ā 

Ā 

GB00BFPM8908

b)

Ā 

Nature of the transaction

Ā 

Purchase of Ordinary Shares

c)

Ā 

Price(s) and volume(s)

Ā 

Ā 

Ā 

Price

Volume

61.6 pence

8,105

61.9 pence

8,066

61.9 pence

8,066

63.8 pence

15,663

62.0 pence

48,373

d)

Ā 

Aggregated information

Ā 

- Aggregated volume

Ā 

- Price

Ā 

88,273 Ordinary Shares purchased at a volume-weighted average price of 62.3 pence.

Ā 

Ā 

e)

Ā 

Date of the transaction

Ā 

3 June 2026

f)

Ā 

Place of the transaction

Ā 

London Stock Exchange

Ā 

Ā 

Ā 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Ā 
END
Ā 
Ā 
DSHFFFVLRAIVIIR
Date   Source Headline
18th Nov 20192:02 pmRNSHolding(s) in Company
11th Nov 201911:33 amRNSUltraDEX wins at the Dental Industry Awards 2019
7th Oct 201910:57 amRNSHolding(s) in Company
20th Sep 20197:00 amRNSHalf-year Report - Amendment
19th Sep 20197:00 amRNSInterim Results
17th Jul 20197:00 amRNSCommercial update
11th Jul 20193:33 pmRNSDirector/PDMR Shareholding
8th Jul 20195:02 pmRNSHolding(s) in Company
25th Jun 20198:44 amRNSDirector/PDMR Shareholding
3rd Jun 201911:36 amRNSResult of AGM
17th May 20194:35 pmRNSPrice Monitoring Extension
1st May 20197:00 amRNSAppointment of Chief Financial Officer
18th Apr 20197:00 amRNSFinal Results
26th Mar 20195:17 pmRNSHolding(s) in Company
20th Mar 20197:00 amRNSNotice of Results Update
29th Jan 20197:00 amRNSTrading and Commercial Update
5th Dec 20183:26 pmRNSHolding(s) in Company
5th Dec 20188:12 amRNSHolding(s) in Company
23rd Nov 20187:00 amRNSChange of adviser and directorate update
15th Nov 20187:00 amRNSCommercial update
20th Sep 20187:01 amRNSDirectorate Change
20th Sep 20187:00 amRNSHalf-year Report
16th Aug 20187:00 amRNSTrading update & notice of interim results
13th Aug 201812:17 pmRNSHolding(s) in Company
8th Aug 20182:15 pmRNSHolding(s) in Company
8th Aug 20187:00 amRNSCompletion of Placing and Acquisition
7th Aug 20184:54 pmRNSHolding(s) in Company
7th Aug 201811:24 amRNSHolding(s) in Company
7th Aug 201811:24 amRNSHolding(s) in Company
7th Aug 201810:10 amRNSHolding(s) in Company
6th Aug 201811:51 amRNSResult of General Meeting
23rd Jul 20184:00 pmRNSHolding(s) in Company
20th Jul 20187:00 amRNSPlacing, proposed acquisition and notice of GM
20th Jul 20187:00 amRNSAppointment of Joint Broker
19th Jul 20183:38 pmRNSHolding(s) in Company
18th Jun 20187:00 amRNSIncreased distribution of UltraDEX in Boots, UK
4th Jun 20187:00 amRNSLloyds Pharmacy to list UltraDEX in UK
23rd May 201812:29 pmRNSResult of AGM
21st May 20187:00 amRNS'1000 Companies to Inspire Britain' 2018 report
9th May 20187:00 amRNSAlliance Pharma contract expansion and extension
8th May 20182:54 pmRNSHolding(s) in Company
30th Apr 20187:00 amRNSUltraDEX update
17th Apr 20187:00 amRNSDirector/PDMR Shareholding
5th Apr 20187:00 amRNSDirector/PDMR Shareholding
27th Mar 20187:00 amRNSDirector/PDMR Shareholding
26th Mar 20187:00 amRNS2018 LTIP and Grant of Options to PDMRs
22nd Mar 20187:00 amRNSFinal Results
5th Mar 20187:00 amRNSNotice of analyst & investor results briefings
16th Feb 20187:00 amRNSInvestor presentation
13th Feb 20187:00 amRNSCommerical update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.